Dr. Ajay Gupta, M.B., B.S., M.D.

EDUCATION

Undergraduate Hansraj College, University of Delhi
1974-1975 B.Sc. (Honors) – Zoology, with additional Physics – 1st yr.
Medical All India Institute of Medical Sciences, New Delhi
1975-1979 Bachelor of Medicine and Bachelor of Surgery (M.B., B.S.)

Post Graduate

1979-1980 Intern, All India Institute of Medical Sciences, New Delhi.
1981-1983 Resident in Medicine, All India Institute of Medical Sciences, New Delhi.
1984 Chief Resident in Medicine, All India Institute of Medical Sciences, New Delhi.
1985-1986 Chief Resident (Registrar) in Medicine, Horton General Hospital, Banbury, U.K.
1986-1988 Clinical Fellow in Nephrology, Wayne State University School of Medicine, Detroit, MI.
1988-1990 Research Fellow in Nephrology, Washington University School of Medicine, St. Louis, MO.

PROFESSIONAL AND FACULTY APPOINTMENTS

1990-1991 Instructor, Department of Medicine, Division of Nephrology, Jewish Hospital, Washington University School of Medicine, St. Louis, Missouri
1991-1993 Assistant Professor of Medicine, SUNY Health Sciences CenterChief, Nephrology Section, Veterans Affairs Medical Center Syracuse, New York
1993-1995 Assistant Professor of Medicine, University of Alabama at Birmingham Director, Dialysis Unit, Veterans Affairs Medical Center, Birmingham, Alabama
1995-2001 Senior Staff Physician, Henry Ford HospitalMedical Director, Clara Ford Hemodialysis FacilityDetroit, Michigan
2001 Associate Professor of Medicine,
June 2009 Charles R. Drew University of Medicine and Science (CDU)
2002 Health Sciences Associate Clinical Professor,
Present David Geffen School of Medicine, University of California, Los Angeles (UCLA)
2002-2005 Associate Chief, Division of Nephrology & HypertensionKing/Drew Medical Center, Los Angeles, California
June 2005- Acting Chief, Division of Nephrology & Hypertension
June 2006 King/Drew Medical Center, Los Angeles, California
June 2006- Acting Chief, Division of Nephrology & Hypertension
August 2006 Martin Luther King Jr.- Harbor Medical Center, Los Angeles, California
2005-2006 Interim Medical Director, Renal Advantage Inc. Dialysis Center, Compton, Los Angeles
2007-Present Medical Director, Renal Advantage Inc. Dialysis Center, Compton, Los Angeles
Sept 2006- Physician Specialist- Nephrology & Hypertension
June 2009 Martin Luther King Jr.- Multispeciality Ambulatory Care Center (MLK-MACC), Los Angeles, California
June 2009- Chief Scientific Officer,
Present Rockwell Medical (www.rockwellmed.com)Wixom, Michigan
2011 Associate Clinical Professor of Medicine,
Present University of California at Irvine (UCI)

BOARD CERTIFICATIONS

1983 Doctor of Medicine (Internal Medicine), (Indian equivalent of Internal Medicine Boards, ABIMAll India Institute of Medical Sciences, New Delhi
1994 Diplomate in Internal Medicine, American Board of Internal Medicine
2004 Recertification, Diplomate in Internal Medicine, American Board of Internal Medicine
1997 Diplomate in Nephrology, American Board of Internal Medicine
2004 Recertification: Diplomate in Nephrology, American Board of Internal Medicine

INVESTIGATOR INITIATED STUDIES:

“Physiological Iron Maintenance of ESRD Subjects By Delivery of Soluble Ferric Pyrophosphate (SFP) via Hemodialysates”; NIH/NIDDK RO1 DK066361-01
Priority score: 175; Percentile: 6.4
Ajay Gupta, M.D., Principal Investigator 7/1/06 – 01/31/-09, $455,252 (direct costs)
The study is currently sponsored by Rockwell Medical Technologies, Inc., Wixom, MI

PHARMACEUTICAL INDUSTRY SPONSORED STUDIES (CLOSED IN THE PAST 5 YEARS)

  1. Nabi-1371, A Phase 3, mulicenter, randomized, placebo-controlled, double-blinded study to evaluate efficacy of staphVAX®, a bivalent staphylococcus aureus glycoconjugate vaccine in adults on hemodialysis. Sponsored by Nabi Pharmaceuticals, Rockville, Maryland;Ajay Gupta,, M.D., Co-Investigator, 2004- 2005
  2. A Multi-center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients”; Luitpold Pharmaceuticals, Inc.;Ajay Gupta, M.D., Principal Investigator; 2008 – 2009
  3. Amgen # 20040259: A randomized, open-label, study to assess the safety of epoetin alfa manufactured by deep tank and epoetin alfa manufactured by a roller bottle technology in subjects with chronic kidney disease not on dialysis;Ajay Gupta, M.D., Principal Investigator, 2005
  4. “A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated with Epoetin Alfa”; Affymax, Inc.;Ajay Gupta, M.D., Principal Investigator; 2008 – 2009
  5. “A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of AF37702 Injection for the Correction of Anemia in Patients with Chronic Renal Failure (CRF) not on Dialysis and not on Erythropoiesis Stimulating Agent (ESA) Treatment”; Affymax, Inc.;Ajay Gupta, M.D., Principal Investigator; 2008 – 2009
  6. “A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Using Genz-644470 and Sevelamer Carbonate in Hyperphosphatemic Chronic Kidney Disease Patients on Hemodialysis”; Genzyme Corporation;Ajay Gupta, M.D., Principal Investigator; 2009
  7. “A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center, Withdrawal Study Comparing MCI-196 Versus Placebo Following A 12-week Dose Titration Period With MCI-196 In Chronic Kidney Disease (Stage V) Subjects On Dialysis (Hemodialysis or Peritoneal Dialysis) With Hyperphosphatemia’; Mitsubishi Pharma Corporation;Ajay Gupta, M.D., Principal Investigator; 2008 – 2009
  8. “Evaluation Of Cinacalcet HCI Therapy to Lower CardioVascular Events”; Amgen Inc.;Ajay Gupta, M.D., Principal Investigator; 2007 – 2009.

INVESTIGATOR INITIATED STUDIES (PAST)

  1. Dialysis Clinics Inc. – “A novel 32K GTP-binding protein in kidney cells.”September 1991 – September 1993, $110,000 / 2 year period
  2. Hendrick’s Fund (Internal grant from State University of New York, Syracuse) -“Small Mr G proteins in kidney that are substrates for C3 exoenzyme.”July 1992- June 1994, $20,000 / 2 year period
  3. American Heart Association, N.Y. Affiliate -“A novel 32K GTP-binding protein in kidney cells.” July, 1993 – June 1995, $60,000 / 2 year period
  4. Small Projects Fund, Henry Ford Hospital-“Hip fractures in end stage renal disease.”September 1995 – September 1997, $9,959 / 2 year period
  5. Small Projects Fund, Henry Ford Hospital-“A clinical trial of low dose oral calcitriol for the treatment of adynamic bone disease in patients on continuous ambulatory peritoneal dialysis.”September 1996 – September 1998, $9,959 / 2 year period
  6. National Kidney Foundation of Michigan, Inc.“Dialysate iron therapy for iron deficiency in ESRD.”July 1997 – June 1998, $20,000 / 1 year period.
  7. National Kidney Foundation of Michigan, Inc.“Pharmacokinetics of iron delivery via the dialysateJuly 1999 – June 2000, $25,000 / 1 year period.
  8. NIH/MBRS – Minority Biomedical Research Support ProgramS06 GM068510 – 1/18/03 – 7/31/07 – $2,906,743Ted Freidman, M.D., Ph.D. – (P.I. – Program Director)

    “Generation of Type I Collagen Cross-Linked Telopeptides, A Novel Marker of Bone Turnover in End-Stage Renal Disease Receiving Peritoneal Dialysis”

    Wang, Jinghua, M.D., Ph.D. (P.I. on Sub-Project)

    8/01/03 – 6/30/06 – $90,000.

    Gupta, Ajay, M.D. – Role on Project: Mentor – 5% Effort

PROFESSIONAL & SCIENTIFIC SOCIETY MEMBERSHIP

  1. American Society of Nephrology
  2. European Renal Association
  3. National Kidney Foundation
  4. Indian Society for Bone and Mineral Research

LEADERSHIP POSITIONS

  1. Chairman and Founder, Indian Society for Bone and Mineral Research (ISBMR), (https://isbmr.in9.cdn-alpha.com). 1996-2008In mid-1990s there was no awareness of osteoporosis in India as a public health problem. The entire country did not have a single DEXA and norms for bone density amongst Asian Indians were not known. In my article “Osteoporosis in India – The nutritional hypothesis”. Nat. Med. J. India, 1996 I proposed that osteoporosis was a major public health problem in India secondary to an epidemic of calcium and vitamin D malnutrition. ISBMR serves the following objectives.
    1. To bring together general physicians, endocrinologist, nutritionists, nephorologists, pediatricians, pathologists, radiologists, gynecologists, rheumoatologists and orthopedic surgeons so that a multidisciplinary approach may be used for prevention and research in metabolic bone disease.
    2. To disseminate knowledge about metabolic bone diseases to the medical community by means of lectures, seminars, and publications, and to general public by the medium of magazines articles, public lectures and distribution of literature.
    3. To conduct and promote research on metabolic bone disease using epidemiological, clinical and basic science approaches.
    4. To establish centers for the diagnosis and treatment of metabolic bone disease.
    5. To work with governmental and nongovernmental agencies on public health issues related to metabolic bone diseases.
    6. Training of Indian physicians interested in metabolic bone disease.
  2. Chairman, Scientific Advisory Board for the study of “Physiological Iron Replacement in ESRD Patients by Delivery of Soluble Ferric Pyrophosphate via Hemodialysis Solutions”, Rockwell Medical Technologies, Inc., Wixom, Michigan. 2005-2009
  3. Chairman, Research Committee, Southern California Kidney Foundation, 2003-06

COMMITTEE MEMBERSHIPS (PAST)

  1. American Heart Association, Western States Affiliate Peer Review Committee, Burlingame, California 2003-04
  2. Member, Executive Academic Committee, Department of Internal Medicine, Charles R. Drew University of Medicine and Sciences, Los Angeles, CA, 2007

PATENTS ISSUED/FILED/LICENSED

  1. Gupta A: Method and pharmaceutical composition for replacing iron losses in hemodialysis patients. US 6,689,275 B1, Feb. 10, 2004 (Issued).LICENSED TO Rockwell Medical Technologies, Inc., Wixom, Michiganhttp://www.rockwellmed.com; stock symbol: RMTI
  2. Gupta A: Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients. US 6,779,468 B1, Aug. 24, 2004 (Issued).LICENSED TO Rockwell Medical Technologies, Inc., Wixom, Michiganhttp://www.rockwellmed.com; stock symbol: RMTI
  3. Gupta A: Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients. EP 0 951 470 B1, Nov. 30, 2005 (Issued).LICENSED TO Rockwell Medical Technologies, Inc., Wixom, MichiganThe embodiment of inventive concept in patents 1,2 and 3 is the administration via hemodialysate of soluble ferric pyrophosphate (SFP), A Unique Parenteral Iron Supplement.

    Since the development of parenteral iron complexes dating back to the 1860’s, SFP is the first and only simple iron salt shown to be safe and effective when administered directly into the circulation in human beings. A 6-month FDA Phase II study concluded that the delivery of SFP slowly into the circulation of hemodialysis patients by addition of only 12 microgram of iron as SFP per deciliter of hemodialysate is safe and effective During over 700 such clinical administrations no adverse reactions related to SFP were observed. The lack of toxicity of SFP is also supported by toxicology studies performed in three species including rats, rabbits and dogs. These studies, both clinical and toxicological have shown that SFP does not cause liver or other organ toxicity in doses substantially greater than therapeutically effective. Soluble ferric polyphosphate is a simple iron salt and not a large polymeric complex. SFP in the circulation is metabolized in a physiological manner, similar to the handling of dietary iron absorbed from the gut. SFP binds directly to transferrin, the circulating iron carrier which transports the iron in SFP to the bone marrow for hemoglobin generation. Unlike polymeric IV iron complexes, SFP does not require uptake and processing by the liver to make it biologically available In other words, unlike the polymeric iron complexes, the body does not perceive or handle SFP as a foreign, particulate matter.

    Furthermore, SFP is likely to be devoid of the adverse side effects for polymeric iron complexes such as 1. acute adverse reactions from release of free, labile, or catalytically active iron, 2. liver accumulation and toxicity, 3. permissive effect on hepatitis C, and 4. enhancement of vascular calcification or calciphylaxis, because of entirely different mode of action that does not involve processing by the liver’s scavenger phagocytic cells or depletion of pyrophosphate from the circulation.

  4. Gupta A: Method and combination electronic communication and medical diagnostic apparatus for detecting/monitoring neuropathy. U.S. Priority App. S.N. : 10/725,393, Dec. 3, 2003 (Issued).PCT/US04/26730 –: Sept. 10, 2004 (Filed).Diabetic neuropathy is unfortunately often not diagnosed until patient develops symptoms. The delay in diagnosis of this devastating disease is caused by the inaccuracy, poor sensitivity, difficulty of use or poor availability of diagnostic tools such as tuning fork, vibrameter and nerve conduction studies. The embodiment of inventive concept in the Gupta patents is a device that solves both of the problems of the tuning fork and the vibrameter. This device integrates with cellular phones, PDA’s, pagers and PDA cell phone devices. The existing vibration function of these items, which many physicians already carry, has been integrated into a simple device that can provide simple and accurate diagnosis of neuropathy. A 4th generation prototype of the device has been developed in collaboration with Daviscomm Inc, UK.
  5. Gupta A: Parenteral administration of pyrophosphate for prevention or treatment of phosphate or pyrophosphate depletion. Appl No. 11/028,114; 12/30/2004 (Filed), claims benefit of 60/481,840; 12/30/2003 (Filed).
  6. Gupta A: Intravenously administrable iron supplement. U.S. Priority App. S.N. : 60/753,815; Dec. 23, 2005 (Filed).
  7. Gupta A: Parenteral Nutrition Composition Containing Iron. Filed Dec. 2006. Claims the benefit of U.S. Provisional Patent Application 60/753,815, filed December 23, 2005.Iron is often necessary in patients receiving long-term parenteral nutrition therapy, but cannot be administered as an additive to parenteral nutrition admixtures because it leads to increase in fat globule size and thereby 1. capillary blockage and a pulmonary embolism like syndrome and 2. Destabilization of the admixture. Soluble ferric pyrophosphate (SFP) has a high stability constant (log Kstab=22.2) that limits the dissociation of destabilizing ferric ions and results in stable lipid injectable emulsion-containing PN admixtures. The embodiment of inventive concept is the administration of SFP as a component of TPN admixtures in order to prevent or treat iron deficiency in patients receiving parenteral nutrition.
  8. Gupta A. Composition And Methods For Treatment Of Renal Disease. Filed March 2010. Claims the benefit of U.S. Provisional Patent Application 61/211,051, filed March 26, 2009.

PUBLICATIONS

  1. Talwar KK, Gupta A: Spontaneous vagal mediated atypical AV nodal Wenckebach block. Indian J. Chest. Dis. and All. Sci. 26:54‑56, 1984.
  2. Gupta A, Migdal SD: Hepatorenal syndrome. Am. J. Med. 83:1173‑1174, 1987.
  3. Gupta A, Hruska KA, Wedner HJ: Phytohemagglutinin rapidly lyses S49 T‑lymphoma cells and the cytotoxicity is not mediated by generation of cAMP or increase in cytosolic calcium. Biochem. Biophys. Res. Commun. 170:1035‑1043, 1990.
  4. Gupta A, Hruska KA: Hyperphosphatemia. Principles and Practice of Nephrology. Jacobson HR, Striker GE, Klahr S (eds.). B. C. Decker, Inc., PA, 1990.
  5. Gupta A, Hruska KA: Hypophosphatemia. Principles and Practice of Nephrology. Jacobson HR, Striker GE, Klahr S (eds.). B. C. Decker, Inc., PA, 1990.
  6. Gupta A, Hruska KA: Hyperphosphatemia and hypophosphatemia. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Favus MJ (ed.). American Society for Bone and Mineral Research, Kelseyville, CA, Chapter 51, pp. 143‑147, 1990.
  7. Dunlay R, Civitelli R, Miyauchi A, Dobre CV, Gupta A, Goligorsky M, Hruska KA: Parathyroid hormone receptor coupling to phospholipase C is an alternate pathway of signal transduction in the bone and kidney. Calcium Regulation and Bone Metabolism, Cohn DV , Glorieux FH , Martin TJ (eds.). Elsevier Science Publishers, 1990, pp. 24‑31.
  8. Gupta A, Martin KJ, Miyauchi A, Hruska KA: Regulation of cytosolic calcium by PTH and oscillations of cytosolic calcium in fibroblasts from normal and pseudohypoparathyroid patients. Endocrinology 128(6):2825‑2836, 1991.
  9. Gupta A, Bastani B, Purcell H, Hruska K A: Identification and localization of pertussis toxin sensitive GTP binding proteins in bovine kidney glomeruli. J. Am. Soc. Nephrol. 2(2): 172‑178, 1991.
  10. Gupta A, Bastani B, Chardin P, Hruska KA: Localization of ral, a small Mr GTP‑binding protein to collecting duct cells in bovine and rat kidney. Am. J. Physiol. 261 (Renal Fluid Electrolyte Physiol. 30): F1063‑F1070, 1991.
  11. Gupta A, Hruska KA, Martin KJ: Neurotensin binding to human embryonic fibroblasts leads to transient elevation of cytosolic calcium. J. Receptor Res. 14(5), 307-317, 1994.
  12. Gupta A, Hruska KA, Tuan TL: Angiotensin II binding to human embryonic lung fibroblasts causes transient changes in cytosolic calcium and promotes fibrin gel contraction. Indian J. Exp. Biol. 32:603-606, 1994.
  13. Gupta A, Cosper P: Renal cancer complicating acquired cystic kidney disease. J. Am. Soc. Nephrol. 5(6):1407-1408, 1994.
  14. Gupta A, Karak P, Saddekni S: Translumbar inferior vena cava catheter for long-term hemodialysis. J. Am Soc. Nephrol. 5:2094-2097, 1995.
  15. Gupta A: Osteoporosis in India – The nutritional hypothesis. Nat. Med. J. India 9(6):268-274, 1996.
  16. Gupta A: Oral iron therapy in hemodialysis patients and the new NKF-DOQI clinical practice guidelines [Letter]. Am. J. Kid. Dis. 31(3):556-557, 1998.
  17. Gupta A, Amin N, Besarab A, Divine G, Susan V, Yee J, Anandan JV: Dialysate iron therapy: Infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int. 55:891-898, 1999.
  18. Gupta A, Kallenbach LR, Zasuwa G, Divine GW: Race is a major determinant of secondary hyperparathyridism in end stage renal disease. J. Am. Soc. Nephrol: 11: 330-334, 2000.
  19. Gupta A: Pathogenesis of anaphylactoid reactions to intravenous iron [Letter]. Am. J. Kid. Dis. 35(2), 360-361, 2000.
  20. Gupta A: Iron infusion into the arterial blood line during hemodialysis: A novel method to remove free iron and reduce oxidative damage. Nephrol. Dial. Transplant: 15:1482-1484, 2000.
  21. Besarab A, Amin A, Ahsan M, Vogel SE, Zasuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J. Am. Soc. Nephrol: 11: 530-538, 2000.
  22. Gupta A, Crumbliss AL: Treatment of iron deficiency anemia: Are monomeric iron compounds suitable for parenteral administration? J. Lab. Clin. Med. 136: 371-378, 2000.
  23. Gupta A: Renal bone disease in black dialysis patients: Are algorithms developed for white dialysis patients valid? Nephrol. Dial. Transplant 17: 1518-1519, 2002.
  24. Gupta A: Does iron depletion induced by erythropoietin slow the progression of chronic kidney disease? Nephrol. Dial. Transplant.17: 175-176, 2002.
  25. Gupta A, Wang J, Norris K: Serum calcium and total calcium load in chronic kidney disease. Nephrol News & Issues. 68-78, Nov. 2003.
  26. Mehrotra R, Budoff M, Christenson P, Ipp E, Takasu J, Gupta A, Norris K, Adler S. Determinants of coronary artery calcification in diabetics with and without nephropathy. Kidney Int. 66(5), 2022-31, 2004
  27. Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, Gupta A, Norris K, Ketteler M, Adler S. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int. 67(3):1070-7, 2005.
  28. Gupta A, Heslin K. Racial differences in response to cinacalcet as a treatment for uremic hyperparathyroidism. Kidney Int 69: 1094, 2006
  29. Omije D, Norris K, Wang J, Pan D, Kermah D and Gupta A. Race is a major determinant of secondary hyperparathyroidism in uremic patients: comparative study of blacks and Hispanics. Clinical Nephrology 70(4), 312-318, 2008.
  30. Tolouian R, Hernandez GT, Chiang W-Y, Gupta A. A new approach for evaluating bone turnover in chronic kidney disease. European Journal of Internal Medicine 21(3), 230-232, 2010.
  31. Tolouian R, Rao DS, Goggins M, Bhat S, Gupta A. Seasonal variation of vitamin D in patients on hemodialysis. Clinical Nephrology 74(1), 19-24, 2010.
  32. Gupta A, Zhuo J, Zha J, Reddy S, Olp J, Pai A: Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrology 11:16, 2010.

ABSTRACTS

(not yet published as a manuscript)

  1. Shetty A, Amin MB, Zasuwa G, Hawkins J, Gupta A. Peritoneal dialysis with solutions containing soluble ferric pyrophosphate for iron supplementation in rabbits. J. Am. Soc. Nephrol. 10: 218A, 2000.
  2. Driscoll D, Joy J, Silvestri A, Nelson D, Gupta A, Bistrian B. Stability of lipid injectable emulsion-based parenteral nutrition admixtures with a novel parenteral iron dosage form. Presented at Annual Meeting and Exposition of American Association of Pharmaceutical Scientists, 2006.
  3. Gupta A, Yocum R, Holberg W, Mosley B, Starr J, Nelson D, Crumbliss A. Fe(III) Transfer from Soluble Ferric Pyrophosphate (SFP) to Human Apotransferrin. American Society of Nephrology, San Diego, 2009.
  4. Gupta A, Yocum R, Guss C, Fishbane S, Besarab A. Continuous Delivery Of Soluble Ferric Pyrophosphate (Sfp) Via The Dialysate Maintains Iron Balance In Chronic Hemodialysis Patients: A Phase II Clinical Trial” ERA-EDTA Congress, organised in collaboration with the Deutsche
    Gesellschaft für Nephrologie (DGfN) in Munich, Germany, June, 2010.
  5. Gupta A, Yocum RC, Guss CD, Ouseph R, Agarwal R. Reduced ESA Requirement by Continuous Delivery of Soluble Ferric Pyrophosphate (SFP) via Dialysate in CKD-HD Patients. Accepted for presentation at American Society of Nephrology, Denver, Nov 2010.
  6. Singh AK, Yocum RC, Guss CD, Smith MT, Gupta A. IV Iron Therapy Leads to Iron Overload in CKD-HD Patients. Accepted for presentation at American Society of Nephrology, Denver, Nov 2010.

INVITED LECTURES AND SYMPOSIA

(Representative of over 50)

  1. “Osteoporosis in India, The Nutritional Hypothesis”. Annual Conference of Endocrine Society of India, Lucknow, India, 1997.
  2. “Iron Administration via the dialysate: A novel and potentially safer alternative to IV iron”. American Society of Nephrology Annual Meeting, Philadelphia, PA, 1999.
  3. “Iron Administration via the dialysate: A novel and potentially safer alternative to IV iron”. Abbott Laboratories Inc., Abbott Park, IL, 2003.
  4. “Iron Administration via the dialysate: A novel and potentially safer alternative to IV iron”. Amgen Inc., Thousand Oaks, CA, 1999.
  5. “Iron Administration via the dialysate: A novel and potentially safer alternative to IV iron” Research Seminar, Department of Medicine, King/Drew Medical Center, Los Angeles, 2001
  6. “Iron Administration via the dialysate: A novel and potentially safer alternative to IV iron” Taiyo Kagaku, Yokkaichi, Japan, 2002.
  7. Nephrology Grand Rounds: “Iron Administration via the dialysate: A novel and potentially safer alternative to IV iron”. Cedar Sinai Medical Center, Los Angeles, CA, 2003.
  8. Nephrology Grand Rounds: “Iron Administration via the dialysate: A novel and potentially safer alternative to IV iron”. Harbor UCLA Medical Center, Torrance, CA, 2003.
  9. “Iron Administration via the dialysate: A novel and potentially safer alternative to IV iron”. Baxter Healthcare, Evanston, IL, 2003.
  10. “Administration of vitamins and carnitine via the dialysate in hemodialysis and peritoneal dialysis patients”. Baxter Healthcare, Evanston, IL, 2003.
  11. Moderator, Working group on Dialysate Iron therapy. American Society of Nephrology Annual Meeting, San Diego, CA, 2003.
  12. Medical Grand rounds: “Acute Renal Failure”. White Memorial Hospital, Los Angeles, CA., 2003.
  13. “Progression Of Chronic Kidney Disease”, Medical Grand Rounds, King/Drew Medical Center, 2003.
  14. “Administration Of Vitamins And Carnitine Via The Dialysate In Hemodialysis And Peritoneal Dialysis Patients”. Minntech Inc., Minneapolis, Minnesota, 2004.
  15. “Potential Role Of Pyrophosphate In Renal Osteodystrophy And Vascular Calcification”. Minntech Inc., Minneapolis, Minnesota, 2004.
  16. “Optimal Parathyroid Hormone Levels In ESRD”. Nephrology Grand Rounds, Harbor UCLA Medical Center, Torrance, CA, June 2005.
  17. “Potential Role Of Pyrophosphate In Renal Osteodystrophy And Vascular Calcification”. Baxter Healthcare, Inc., Deerfield, Illinois, 2005.
  18. “Optimal Parathyroid Hormone Levels In ESRD and Racial Differences”. Endocrinology Grand Rounds, King/Drew Medical Center, Los Angeles, CA, March 2006.
  19. “Role Of Kidney In The Pathogenesis Of Hypertension And Patho-Physiology Of Hypertension Induced Renal Injury. Nephrology” Pathophysiology Course, UCLA Divisions of Nephrology, West LA Veterans Affair Medical Center, Los Angeles, California. March 2006
  20. “Physiological Iron Maintenance in ESRD Subjects by Delivery of Soluble Ferric Pyrophosphate via Hemodialysate”. Medical Grand Rounds, University of Malay, Kualalampur, Malaysia, 2006.
  21. “Hypertensive Urgency and Emergency” Medical Grand Rounds, King/Drew Medical Center, Nov. 2006.
  22. Nephrology Grand Rounds: “Role of Pyrophosphate in Vascular Calcification”. Harbor UCLA Medical Center, Torrance, CA, Feb. 2007.
  23. “Vascular Calcification – Clinical Features and Pathogenesis” Medical Grand Rounds, Martin Luther King Harbor Hospital, March 2007.